Skip to content

Changes in male fertility during chronic illness

Investigating how chronic illness affects markers of reproductive function in men with infertility

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN17222161
Enrollment
50
Registered
2017-04-05
Start date
2016-09-01
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Male infertility Urological and Genital Diseases Male infertility

Interventions

Part 1 (Observational component): Participants will be asked to attend a single visit at the Andrology Unit, Hammersmith Hospital. Visit will take approximately one and half our, and will consist of:

Sponsors

AHSC Joint Research Compliance Office
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Inclusion Criteria (study 1 only) 1. Male 2. 18-60 years of age 3. Participants in the following groups will be recruited: Control Group: Healthy participants Disease Groups: Participants with chronic diseases e.g. diabetes mellitus, obesity Inclusion Criteria (study 2 only) 1. Male 2. Known infertility 3. 18-60 years of age 4. Current lifestyle factors known to affect fertility (e.g. any raised BMI, smoking, recreational drug use, excessive alcohol intake) which remain despite any previous lifestyle advice gained in the NHS

Exclusion criteria

Exclusion criteria: 1. History of anaemia 2. Needle-phobia 3. Acute illness likely to affect the result of study 4. Impaired ability to provide full consent to take part in the study

Design outcomes

Primary

MeasureTime frame
Part 1: Sperm count abnormalities will be measured using routine semen analysis at baseline. Part 2: Sperm count abnormalities will be measured using routine semen analysis at baseline, 2, 3, 4 and 5 weeks.

Secondary

MeasureTime frame
Part 2: 1. Weight, measured using scales at baseline, 2, 3, 4 and 5 weeks 2. Serum reproductive hormones using automated immunoassays at baseline, 2, 3, 4 and 5 weeks 3. Serum metabolic parameters using automated immunoassays at baseline, 2, 3, 4 and 5 weeks

Countries

England, United Kingdom

Contacts

Public ContactChanna Jayasena
c.jayasena@imperial.ac.uk+44 20 8383 3242

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026